3 Companies Frightened by This Medicare Study
Todd Campbell, The Motley Fool - Motley Fool - Sun May 18, 6:05AM CDT
Everyone knows that medical costs are soaring, and that those costs present one of the biggest financial challenges to the next generation. But far fewer know that one of the biggest drug buyers, the Centers for Medicare and Medicaid Services, or...
Final Glance: Biotechnology companies
AP - Fri May 16, 5:05PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
After Yesterday's Decline of 1.03%, Celgene Offers Investors Better Value
Comtex SmarTrend(R) - Fri May 16, 3:52PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $145.30 to a high of $150.20. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $148.00 on volume of 2.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Watch for Celgene to Potentially Rebound After Falling 1.03% Yesterday
Comtex SmarTrend(R) - Fri May 16, 3:51PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $145.30 to a high of $150.20. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $148.00 on volume of 2.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Midday Glance: Biotechnology companies
AP - Fri May 16, 12:33PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Early Glance: Biotechnology companies
AP - Fri May 16, 10:47AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Upcoming Conferences, Stock Price Movements and Support to Humanitarian Programs - Analyst Notes on Celgene, Biogen Idec, Incyte, Jazz Pharmaceuticals and Medivation
PR Newswire - Fri May 16, 6:00AM CDT
Today, Analysts Review released its analysts' notes regarding Celgene Corporation (NASDAQ: CELG), Biogen Idec Inc. (NASDAQ: BIIB), Incyte Corporation (NASDAQ: INCY), Jazz Pharmaceuticals plc (NASDAQ: JAZZ) and Medivation Inc. (NASDAQ: MDVN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2548-100free.
Celgene Announces Presentations of Investigational Studies in Solid Tumor and Blood Cancers at ASCO 2014
Business Wire - Wed May 14, 4:19PM CDT
Celgene International Sarl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced more than 65 abstracts reporting on investigational studies in blood and solid tumor cancers will be presented during the 50th American Society of Clinical Oncology meeting in Chicago, Ill. from May 30 to June 3, 2014.
Critical Alerts For DirecTV, JPMorgan, First Solar, Celgene, and Baidu.com Released By InvestorsObserver
PR Newswire - Wed May 14, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for DTV, JPM, FSLR, CELG, and BIDU.
Clinical Trial Results, Acquisitions, Healthcare Partnership, and Pricing of Senior Notes - Analyst Notes on Merck, JNJ, Chelsea, Unitedhealth and Celgene
PR Newswire - Tue May 13, 6:20AM CDT
Today, Analysts Review released its analysts' notes regarding Merck & Co. Inc. (NYSE: MRK), Johnson & Johnson (NYSE: JNJ), Chelsea Therapeutics International Ltd. (NASDAQ: CHTP), Unitedhealth Group, Inc. (NYSE: UNH) and Celgene Corporation (NASDAQ: CELG). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2377-100free.
Celgene Rises 2.63% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon May 12, 4:00PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $145.70 to a high of $151.00. Yesterday, the shares gained 2.6%, which took the trading range above the 3-day high of $147.99 on volume of 3.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
After Yesterday's Rally of 2.63% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon May 12, 3:59PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $145.70 to a high of $151.00. Yesterday, the shares gained 2.6%, which took the trading range above the 3-day high of $147.99 on volume of 3.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Will Patterson (PDCO) Disappoint this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 12, 12:00PM CDT
Patterson's (PDCO) bottom-line growth was on par with the Zacks Consensus Estimate.
Celgene Earnings Review: 18 Days after Announcement Shares Up 3.8% (CELG)
Comtex SmarTrend(R) - Mon May 12, 11:09AM CDT
When Celgene (NASDAQ:CELG) reported earnings 18 days ago on April 24th, 2014, analysts, on average, expected the company to report earnings of $1.65 on sales of $1.8 billion. The company actually reported EPS of $1.67 on sales of $1.7 billion, beating EPS estimates by $0.02 and missing revenue estimates by $35.1 million. Shares of Celgene have climbed from $141.25 to $146.67, representing a gain of 3.8% since the company reported earnings 18 days ago.